1. Home
  2. CHMG vs EDIT Comparison

CHMG vs EDIT Comparison

Compare CHMG & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Chemung Financial Corp

CHMG

Chemung Financial Corp

HOLD

Current Price

$55.25

Market Cap

242.8M

Sector

Finance

ML Signal

HOLD

Logo Editas Medicine Inc.

EDIT

Editas Medicine Inc.

HOLD

Current Price

$2.19

Market Cap

213.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CHMG
EDIT
Founded
1833
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
242.8M
213.8M
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
CHMG
EDIT
Price
$55.25
$2.19
Analyst Decision
Hold
Strong Buy
Analyst Count
2
4
Target Price
$54.50
$4.50
AVG Volume (30 Days)
10.5K
1.7M
Earning Date
01-27-2026
11-10-2025
Dividend Yield
2.46%
N/A
EPS Growth
N/A
N/A
EPS
2.80
N/A
Revenue
$86,610,000.00
$46,383,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$32.65
N/A
P/E Ratio
$19.75
N/A
Revenue Growth
N/A
N/A
52 Week Low
$40.71
$0.91
52 Week High
$60.80
$4.54

Technical Indicators

Market Signals
Indicator
CHMG
EDIT
Relative Strength Index (RSI) 48.87 35.12
Support Level $53.83 $2.12
Resistance Level $60.80 $2.61
Average True Range (ATR) 1.41 0.16
MACD -0.27 -0.01
Stochastic Oscillator 29.36 10.34

Price Performance

Historical Comparison
CHMG
EDIT

About CHMG Chemung Financial Corp

Chemung Financial Corp is a bank holding firm. Through its subsidiaries, the company provides various financial services, including demand, savings, and time deposits, commercial, residential, and consumer loans, letters of credit, wealth management services, employee benefit plans, insurance products, mutual funds, and brokerage services, among others. The company's reportable segments are Core Banking, Wealth Management (WMG) services, and Holding company and CFS. Maximum revenue is generated from the Core Banking segment, which derives revenue by attracting deposits from the general public and using such funds to originate different types of loans, and to invest in securities. The Wealth Management (WMG) services segment provides trust and investment advisory services to clients.

About EDIT Editas Medicine Inc.

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

Share on Social Networks: